Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05739084
Other study ID # ET21-240 [RADIOSARC]
Secondary ID GDPR registratio
Status Recruiting
Phase
First received
Last updated
Start date November 23, 2022
Est. completion date November 23, 2025

Study information

Verified date February 2023
Source Centre Leon Berard
Contact Marie -Pierre SUNYACH, MD
Phone +33(0)4 78 78 28 28
Email MariePierre.SUNYACH@lyon.unicancer.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To date, the radiation oncologist are missing biomarkers predictive of response/resistance to RT in order to identify patients who may benefit from RT and personalize the RT schedule. Our proposal is to conduct a cohort study aiming at identifying transcriptomic biomarkers predictive of sensitivity and/or resistance to RT in limbs STS patients


Description:

Whether RT should be performed pre or post-operatively is still a debated question. To date, the radiation oncologist are missing signature of response/resistance to RT in order to identify patients who may benefit from RT and personalize the RT schedule. Therefore, predicting the likelihood of response/resistance to RT is essential. The individual exploration with high-throughput approaches will participate in describing biological mechanisms involved in STS tumor cell pan-resistance, thus identifying potential molecular targets that could be inhibited to reverse intrinsic radioresistance. In this context, our proposal is to conduct a cohort study aiming at identifying transcriptomic signature predictive of sensitivity and/or resistance to RT in limbs STS patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date November 23, 2025
Est. primary completion date June 23, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male and female = 18 years at time of non-opposition to participate to the study - Patient with documented non-opposition to participate to the study. - Patient with histologically and cytologically confirmed diagnosis with STS (..) - Patient with availability of FFPE tumor block from initial diagnosis biopsy (mandatory) and surgery specimen (optional). - Patients with tumor FFPE samples prepared with the last 4 years - Patient with evaluable tumor sample meeting the following quality/quantity control criteria (..) Exclusion Criteria: - Patients with metastatic soft tissue sarcoma at diagnosis - Patients with exclusive radiotherapy without surgical resection - Patients receiving neo adjuvant systemic treatment (chemotherapy, immunotherapy, targeted therapy)

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
pre-operative radiation
As per standard of care and institutional guidelines
Procedure:
Standard surgery after rpreoprative radiation
As per standard of care and institutional guidelines

Locations

Country Name City State
France Centre Léon Bérard Lyon

Sponsors (1)

Lead Sponsor Collaborator
Centre Leon Berard

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary To define a transcriptomic signature of histological response to radiotherapy in STS patients using the percentage of residual viable cells as a clinical meaningful endpoint Gene expression signature using RNAseq correlated to the percentage of residual viable cells on surgery specimen to define histological response. 36 months
Secondary To identify biomarkers of sensitivity or resistance to radiotherapy in STS patients using additional clinical endpoints Gene expression signature using RNAseq correlated to the percentage of necrosis, the percentage of fibrosis, the local control at 1 and 2 years (1- and 2-year local / distant recurrence-free survival, the time To Relapse (TTR), the Disease Free Survival (DFS), The Quality of resection level based on the residual tumor (R) classification. 36 months
See also
  Status Clinical Trial Phase
Completed NCT00385203 - The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). Phase 2
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Recruiting NCT00687778 - 11C-Acetate PET/CT Non-FDG-Avid Tumors N/A
Recruiting NCT04506008 - Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas Phase 2
Terminated NCT02575066 - Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients Phase 2
Completed NCT04223583 - Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule Phase 4
Recruiting NCT04425967 - Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas N/A
Not yet recruiting NCT03946943 - Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Phase 2
Withdrawn NCT00881595 - Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas Phase 2
Completed NCT00423254 - Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. Phase 1
Completed NCT00276302 - Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) Phase 1
Withdrawn NCT03149120 - Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas Phase 2
Completed NCT01830153 - RAD001 in Advanced Sarcoma Phase 2
Completed NCT02636725 - Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas Phase 2